Clinical Trial Update: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy in participants with pre-existing antibodies to rAAVrh74 has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• SRP-9001 (Delandistrogene Moxeparvovec) (delandistrogene moxeparvovec)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 1 | Status: TERMINATED